Role of T lymphocytes in ischemic brain injury

Takashi Shichita, Fumie Konoeda, Akihiko Yoshimura

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Recently, inflammation has been implicated in the progression of cerebral ischemic injury. Especially, T lymphocytes have been shown to infiltrate into the ischemic brain 24 hours after the onset, however, the function and specific subpopulation of these infiltrated T lymphocytes have not been fully understood. By using cytokine-deficient mice with transient focal ischemia model, we have shown that IL-23 and IL-17 but not IL-6 or IFN-γ play pivotal roles in the ischemic brain injury. We found that IL-23, which was mainly produced from infiltrated macrophages, induced IL-17-producing T lymphocytes in the ischemic brain. IL-23 and IL-17 expression increased 1 day or 3 day after ischemic injury, respectively, and promoted inflammatory responses by increasing the expression of neurotoxic factors. To our surprise, IL-17 was mainly produced by γδT lymphocytes, but not helper T cells. Based on these findings, we have tried to develop new therapeutic strategy for the progression of brain infarction. We found that administration of FTY720 (Fingolimod) and antibody against γδT lymphocytes attenuated ischemic brain damage. Furthermore, antibody against p40 which neutralizes both IL-23 and IL-12 simultaneously was also effective. Therefore, anti-cytokine therapy will be applicable for neuroprotection in the delayed phase of brain ischemia.

Original languageEnglish
Pages (from-to)878-880
Number of pages3
JournalClinical Neurology
Volume50
Issue number11
DOIs
Publication statusPublished - 2010

Fingerprint

Interleukin-23
Interleukin-17
Brain Injuries
T-Lymphocytes
Brain
Cytokines
Brain Infarction
Antibodies
Wounds and Injuries
Interleukin-12
Helper-Inducer T-Lymphocytes
Brain Ischemia
Interleukin-6
Ischemia
Macrophages
Inflammation
Therapeutics
Fingolimod Hydrochloride

Keywords

  • γδT lymphocyte
  • Brain ischemia
  • IL-17
  • IL-23
  • T lymphocyte

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Role of T lymphocytes in ischemic brain injury. / Shichita, Takashi; Konoeda, Fumie; Yoshimura, Akihiko.

In: Clinical Neurology, Vol. 50, No. 11, 2010, p. 878-880.

Research output: Contribution to journalArticle

Shichita, Takashi ; Konoeda, Fumie ; Yoshimura, Akihiko. / Role of T lymphocytes in ischemic brain injury. In: Clinical Neurology. 2010 ; Vol. 50, No. 11. pp. 878-880.
@article{75940eee1bc14fc7b936e46bd40925c9,
title = "Role of T lymphocytes in ischemic brain injury",
abstract = "Recently, inflammation has been implicated in the progression of cerebral ischemic injury. Especially, T lymphocytes have been shown to infiltrate into the ischemic brain 24 hours after the onset, however, the function and specific subpopulation of these infiltrated T lymphocytes have not been fully understood. By using cytokine-deficient mice with transient focal ischemia model, we have shown that IL-23 and IL-17 but not IL-6 or IFN-γ play pivotal roles in the ischemic brain injury. We found that IL-23, which was mainly produced from infiltrated macrophages, induced IL-17-producing T lymphocytes in the ischemic brain. IL-23 and IL-17 expression increased 1 day or 3 day after ischemic injury, respectively, and promoted inflammatory responses by increasing the expression of neurotoxic factors. To our surprise, IL-17 was mainly produced by γδT lymphocytes, but not helper T cells. Based on these findings, we have tried to develop new therapeutic strategy for the progression of brain infarction. We found that administration of FTY720 (Fingolimod) and antibody against γδT lymphocytes attenuated ischemic brain damage. Furthermore, antibody against p40 which neutralizes both IL-23 and IL-12 simultaneously was also effective. Therefore, anti-cytokine therapy will be applicable for neuroprotection in the delayed phase of brain ischemia.",
keywords = "γδT lymphocyte, Brain ischemia, IL-17, IL-23, T lymphocyte",
author = "Takashi Shichita and Fumie Konoeda and Akihiko Yoshimura",
year = "2010",
doi = "10.5692/clinicalneurol.50.878",
language = "English",
volume = "50",
pages = "878--880",
journal = "Clinical Neurology",
issn = "0009-918X",
publisher = "Societas Neurologica Japonica",
number = "11",

}

TY - JOUR

T1 - Role of T lymphocytes in ischemic brain injury

AU - Shichita, Takashi

AU - Konoeda, Fumie

AU - Yoshimura, Akihiko

PY - 2010

Y1 - 2010

N2 - Recently, inflammation has been implicated in the progression of cerebral ischemic injury. Especially, T lymphocytes have been shown to infiltrate into the ischemic brain 24 hours after the onset, however, the function and specific subpopulation of these infiltrated T lymphocytes have not been fully understood. By using cytokine-deficient mice with transient focal ischemia model, we have shown that IL-23 and IL-17 but not IL-6 or IFN-γ play pivotal roles in the ischemic brain injury. We found that IL-23, which was mainly produced from infiltrated macrophages, induced IL-17-producing T lymphocytes in the ischemic brain. IL-23 and IL-17 expression increased 1 day or 3 day after ischemic injury, respectively, and promoted inflammatory responses by increasing the expression of neurotoxic factors. To our surprise, IL-17 was mainly produced by γδT lymphocytes, but not helper T cells. Based on these findings, we have tried to develop new therapeutic strategy for the progression of brain infarction. We found that administration of FTY720 (Fingolimod) and antibody against γδT lymphocytes attenuated ischemic brain damage. Furthermore, antibody against p40 which neutralizes both IL-23 and IL-12 simultaneously was also effective. Therefore, anti-cytokine therapy will be applicable for neuroprotection in the delayed phase of brain ischemia.

AB - Recently, inflammation has been implicated in the progression of cerebral ischemic injury. Especially, T lymphocytes have been shown to infiltrate into the ischemic brain 24 hours after the onset, however, the function and specific subpopulation of these infiltrated T lymphocytes have not been fully understood. By using cytokine-deficient mice with transient focal ischemia model, we have shown that IL-23 and IL-17 but not IL-6 or IFN-γ play pivotal roles in the ischemic brain injury. We found that IL-23, which was mainly produced from infiltrated macrophages, induced IL-17-producing T lymphocytes in the ischemic brain. IL-23 and IL-17 expression increased 1 day or 3 day after ischemic injury, respectively, and promoted inflammatory responses by increasing the expression of neurotoxic factors. To our surprise, IL-17 was mainly produced by γδT lymphocytes, but not helper T cells. Based on these findings, we have tried to develop new therapeutic strategy for the progression of brain infarction. We found that administration of FTY720 (Fingolimod) and antibody against γδT lymphocytes attenuated ischemic brain damage. Furthermore, antibody against p40 which neutralizes both IL-23 and IL-12 simultaneously was also effective. Therefore, anti-cytokine therapy will be applicable for neuroprotection in the delayed phase of brain ischemia.

KW - γδT lymphocyte

KW - Brain ischemia

KW - IL-17

KW - IL-23

KW - T lymphocyte

UR - http://www.scopus.com/inward/record.url?scp=84856398917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856398917&partnerID=8YFLogxK

U2 - 10.5692/clinicalneurol.50.878

DO - 10.5692/clinicalneurol.50.878

M3 - Article

VL - 50

SP - 878

EP - 880

JO - Clinical Neurology

JF - Clinical Neurology

SN - 0009-918X

IS - 11

ER -